Overview

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

Status:
Completed

Trial end date:
2013-10-15

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus meropenem (1000mg q8h)for the treatment of adults with Complicated Intraabdominal Infections (cIAI).

Phase:

Phase 3

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Meropenem
Metronidazole
Thienamycins